drugset

drugset / Trial / NCT05966025

Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

NCT05966025 ↗

Phase 2 Unknown 60 enrolled October 6 University Beni-Suef University · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD

Timeline

Start: 2023-12-28
Primary completion: 2024-12
Completion: 2025-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Itopride	Small molecule	100 mg	—

Indications